Szejko, Natalia http://orcid.org/0000-0001-6160-9221
Robinson, Sally http://orcid.org/0000-0001-8239-4354
Hartmann, Andreas http://orcid.org/0000-0002-0335-984X
Ganos, Christos http://orcid.org/0000-0001-8077-8530
Debes, Nanette M. http://orcid.org/0000-0003-0279-1865
Skov, Liselotte http://orcid.org/0000-0002-2137-0735
Haas, Martina http://orcid.org/0000-0003-3898-5784
Rizzo, Renata http://orcid.org/0000-0002-3997-1328
Stern, Jeremy http://orcid.org/0000-0003-3230-3543
Münchau, Alexander http://orcid.org/0000-0002-3219-2284
Czernecki, Virginie http://orcid.org/0000-0002-0139-7957
Dietrich, Andrea http://orcid.org/0000-0002-2538-6136
Murphy, Tara L. http://orcid.org/0000-0003-1759-3562
Martino, Davide http://orcid.org/0000-0002-2217-0487
Tarnok, Zsanett http://orcid.org/0000-0002-2493-0232
Hedderly, Tammy http://orcid.org/0000-0002-5467-054X
Müller-Vahl, Kirsten R. http://orcid.org/0000-0002-7181-7419
Cath, Danielle C. http://orcid.org/0000-0001-9539-4118
Article History
Received: 8 March 2021
Accepted: 30 June 2021
First Online: 18 October 2021
Change Date: 25 November 2021
Change Type: Update
Change Details: The original publication was revised due to update in article note.
Declarations
:
: CG received research grants from the VolkswagenStiftung (Freigeist Fellowship) and the German Parkinson Society and was also supported by the Deutsche Forschungsgemeinschaft (GA2031/1-1 and GA2031/1-2) and Actelion Pharmaceuticals. He also received financial support/honoraria to speak at meetings by Actelion pharmaceuticals and as ad hoc advisory board for Lundbeck. DM has received personal compensation for consultancies for Sunovion and serves in Advisory Boards of Sunovion and Paladin Labs. He was also granted honoraria from Dystonia Medical Research Foundation Canada and royalties from Springer-Verlag. He was funded grants from Ipsen Corporate, Dystonia Medical Research Foundation Canada, Parkinson Canada, The Owerko Foundation, and the Michael P Smith Family. AH has received consultancy honoraria from Lundbeck and Noema Pharma. He has received research grants from the Association Française pour le Syndrome Gilles de la Tourette (AFSGT). RR has received financial research support from EU (FP7-Health 2011N. 278367. The University of Catania research plan 2016–2018. She has carried out clinical trials in cooperation with Otsuka, Angelini, TEVA companies. DC received grant from the EU (TS EUROTRAIN), grant nr. 316978), several grants from ZONMW and MAGW (the Netherlands), from TSA-USA (2008), from Sunovion (DS028 (2019). From Espria fonds, Drenthe, the Netherlands. She has received speakers’ fees from ECNP, Psyfar, Benecke, Pfizer. KMV has received financial or material research support from the EU (FP7-HEALTH-2011 No. 278367, FP7-PEOPLE-2012-ITN No. 316978), the German Research Foundation (DFG: GZ MU 1527/3-1), the German Ministry of Education and Research (BMBF: 01KG1421), the National Institute of Mental Health (NIMH), the Tourette Gesellschaft Deutschland e.V., the Else-Kröner-Fresenius-Stiftung, and Abide Therapeutics, Almirall Hermal GmbH, GW pharmaceuticals, Lundbeck, Syneos Health, and Therapix Biosciences Ltd.She has received consultant's honoraria from Abide Therapeutics, Bionorica Ethics GmbH, CannaMedical Pharma GmbH, Canopy Grouth, Columbia Care, CTC Communications Corp., Eurox Deutschland GmbH, Global Praxis Group Limited, Lundbeck, Resalo Vertrieb GmbH, Sanity Group, Synendos Therapeutics AG, and Tilray. She is/was a consultant or advisory board member for Abide Therapeutics, The Academy of Medical Cannabis Limited, Alirio, Aphria Deutschland GmbH, CannaMedical Pharma GmbH, Boehringer Ingelheim International GmbH, Bionorica Ethics GmbH, CannaXan GmbH, Canopy Growth, Columbia Care, CTC Communications Corp., Leafly Deutschland GmbH, Lundbeck, Nomovo Pharm, Nuvelution TS Pharma Inc., Resalo Vertrieb GmbH, Sanity Group, Syqe Medical Ltd., Therapix Biosciences Ltd., Tilray, Wayland Group, Zynerba Pharmaceuticals, and CTC Communications Corporation.She has received speaker’s fees from Aphria Deutschland GmbH, Cogitando GmbH, Emalex, Eurox group, Ever pharma GmbH, PR Berater, Tilray, and Wayland Group. She has received royalties from Medizinisch Wissenschaftliche Verlagsgesellschaft Berlin, Elsevier, and Kohlhammer. She holds shares of Nomovo Pharm. She served as a Guest editor for Frontiers in Neurology on the research topic “The neurobiology and genetics of Gilles de la Tourette syndrome: new avenues through large-scale collaborative projects” and is Associate editor for “Cannabis and Cannabinoid Research”, Editorial Board Member for “Medical Cannabis and Cannabinoids” and “MDPI-Reports”, and scientific board member for “Zeitschrift für Allgemeinmedizin”. AM has received commercial research support from: Pharm Allergan, Ipsen, Merz Pharmaceuticals, Actelion. He was granted honoraria for lectures: Pharm Allergan, Ipsen, Merz Pharmaceuticals, Actelion, GlaxoSmithKline, Desitin, Teva, Takeda; consultancies from: Desitin, Merz Pharmaceuticals, Admedicum. He is also supported from the following Foundations: Possehl-Stiftung (Lübeck, Germany), Margot und Jürgen Wessel Stiftung (Lübeck, Germany), Tourette Syndrome Association (Germany), Interessenverband Tourette Syndrom (Germany), CHDI, Damp-Stiftung. He also was funded the following academic research support: Deutsche Forschungsgemeinschaft (DFG): projects 1692/3-1, 4-1, SFB 936, and FOR 2698 (project numbers 396914663, 396577296, 396474989), Innovationsausschuss of the Gemeinsamer Bundesausschuss: Translate NAMSE (structural support for the Lübeck Center for Rare Diseases); European Reference Network—Rare Neurological Diseases (ERN—RND); Royalties for the book <i>Neurogenetics</i> (Oxford University Press). He serves in Advisory Boards of German Tourette syndrome Association and Alliance of patients with chronic rare diseases. All other authors have no conflicts to report.